由于肝衰竭事件，FDA 对 RAPT Therapeutics 的特应性皮炎和哮喘试验进行了临床暂停。 FDA places clinical hold on RAPT Therapeutics' atopic dermatitis and asthma trials due to liver failure event.

由于一名患者出现肝功能衰竭事件，RAPT Therapeutics（纳斯达克股票代码：RAPT）股价暴跌 60% 以上，此前 FDA 暂停了其正在进行的两项实验性炎症治疗药物 zelnecirnon 的临床试验，该试验用于治疗特应性皮炎和哮喘。 RAPT Therapeutics (NASDAQ: RAPT) saw shares plummet by over 60% after the FDA placed a clinical hold on two of its ongoing trials for its experimental inflammation treatment zelnecirnon, in atopic dermatitis and asthma, due to a liver failure event in one patient. 该公司预计将收到 FDA 的正式临床暂停函，这意味着这两项试验的给药和招募都必须停止。 The company expects to receive a formal clinical hold letter from the FDA, which means dosing and enrollment in both trials must be halted.